ClinicalTrials.gg
RecruitingNCT04767490SADIUpdated Aug 9, 2024

Single Anastomosis Versus Standard Duodenal Switch

An interventional study of Standard Duodenal Switch and Single Anastomosis Duodenal Switch in Obesity and Morbid Obesity, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Laval University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 6 months after the study started (first participant enrolled Sep 2015, registered Mar 2018).
  • Started Sep 2015; still recruiting 11 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.

Planned enrollment
4th of 22
120 · median 57
Started
2015
with 1 other
No phase
17 of 32
3 open now
Registered
19th of 32
by date
Lead sponsor
8 of 32
Laval University

Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2015, is one of 17 with no phase, and was the 19th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity, Morbid with a site in Canada, or all of them as a file.
02

Study summary

Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion.

Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a terminal intestinal loop used in standard BPD-DS.

The overall objective of this study is to assess in a prospective randomized blinded trial, the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up method. This could potentially change the clinical practice and surgical approach in our Institution.

Read the detailed description

Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion. Our team, with more than 4000 BPD-DS performed since the early 1990's, is recognized internationally for its expertise with this specific procedure.

Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a terminal intestinal loop used in standard BPD-DS.

This new procedure, called Single Anastomosis Duodenal Switch has the potential benefit of decreasing the complexity of the standard BPD-DS by avoiding one of the two intestinal anastomoses usually needed. This could potentially decrease the rate of peri-operative complications and increase access to this type of surgery.

However, the length of the common channel (250cm) is more than doubled compared to standard BPD-DS, which could also change significantly the outcomes of the procedure itself. Indeed, the length of the common channel conditions the absorption of fat and fat-soluble vitamins.

Currently, the scientific literature regarding this procedure is scarce, with only one author who published his 2-years outcomes, in a cohort study of 100 patients. In addition, this report presents major limitations. In example, the length of the omega loop was increased from 200 to 250cm during the course of the study, in order to decrease the rate of protein deficiency and reoperation for malnutrition. This and other limitations make it hard to assess the actual results of the technique.

The overall objective of this study is to assess in a stronger study design (i.e. a prospective randomized single blinded trial), the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up method. This could potentially change the clinical practice and surgical approach in our Institution.

03

Conditions studied

  • Obesity
  • Morbid Obesity

Browse trials for

Keywords

  • bariatric surgery
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 120 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤60 years
  • Fulfill criteria for bariatric surgery as coined by National Institutes of Health ≥35
  • Give written

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria at the time of the baseline visit are excluded from the study:

  • Presence of the following baseline comorbidities:
  • Inflammatory bowel disease (IBD),
  • Cirrhosis
  • History of gastric or duodenal ulcers
  • Preoperative hypoalbuminemia (\<35 g/L)
  • History of severe renal, hepatic, cardiac or pulmonary disease
  • Past esophageal, gastric or bariatric surgery
  • Type 1 Diabetes
  • Pregnancy
  • Evidence of psychological problem that may affect the capacity to understand the project and to comply with the medical recommendations
  • History of drug use or alcohol abuse in the last 6 months
  • History of gastro-intestinal inflammatory diseases
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    BPD-DS

    Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb

    Procedure: Standard Duodenal Switch

  • Experimental
    SADI

    Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel

    Procedure: Single Anastomosis Duodenal Switch

Interventions

  • ProcedureStandard Duodenal Switch

    Also known as: BPD-DS

  • ProcedureSingle Anastomosis Duodenal Switch

    Also known as: SADI

07

What researchers measure

Primary outcomes

  1. Excess weight loss

    Excess weight loss at 2 years of follow-up %EWL (Excess weight loss based on an ideal BMI = 25.) and change in BMI as compared to preoperative reference values

    Time frame: 2 years

  2. Rate of protein deficiency or insufficiency

    Rate of protein deficiency (\<35gr/l) or insufficiency (\<30gr/l)

    Time frame: from baseline up to 60 months

  3. Mortality rate

    Rate of mortality

    Time frame: from baseline up to 60 months

  4. BMI

    change in BMI at 2 years follow-up as compared to preoperative reference values

    Time frame: 2 years

Secondary outcomes

  1. Complication rate

    overall and surgery-specific complications

    Time frame: from baseline up to 60 months

  2. Cure rate of comorbidities

    Remission rate for comorbidities, including T2D, Hypertension, dyslipidemia, sleep apnea

    Time frame: from baseline up to 60 months

  3. Rate of minerals and vitamin deficiencies

    Rate of deficiency and insufficiency in mineral and vitamins

    Time frame: from baseline up to 60 months

  4. Body composition by bioimpedance measures

    body fat composition (%) assessed by biompedance

    Time frame: from baseline up to 60 months

  5. Change in quality of life

    36-item short form survey score from 0 to 100

    Time frame: from baseline up to 60 months

  6. Change in quality of life

    Bariatric Analysis and Reporting Outcomes System score from -7 to 9

    Time frame: from baseline up to 60 months

  7. Change in quality of life

    Laval Questionnaire score from 0 to 7

    Time frame: from baseline up to 60 months

  8. Change in quality of life

    GastroIntestinal Quality of Life Index from 0 to 144

    Time frame: from baseline up to 60 months

  9. Change in gatroesophageal reflux symptom

    GastroEsophageal Reflus Disease Score from 0 to 72

    Time frame: from baseline to 60 months

08

Study locations

1 of 1 sites recruiting
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
    Quebec City, Quebec G1V 4G5, Canada
    Recruiting
    • Suzy Laroche · Contactsuzy_laroche@ssss.gouv.qc.ca · 418-656-8711
    • Laurent Biertho, MD · Principal investigator
    • Simon Marceau, MD · Sub investigator
    • Simon Biron, MD · Sub investigator
    • Stéfane Lebel, MD · Sub investigator
    • François Julien, MD · Sub investigator
    • Odette Lescelleur, MD · Sub investigator
    • André Tchernof, MD · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Sep 2025, 120 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 120 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Feb 23, 2021
StartActual
Sep 1, 2015
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 1, 2026
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04767490
Lead sponsor
Laval University
Collaborators
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Laurent Biertho (Principal Investigator, Laval University) — Principal investigator
First posted
Feb 23, 2021
Start date
Sep 1, 2015
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Aug 9, 2024

Study contacts

Suzy Laroche
Contact
suzy_laroche@ssss.gouv.qc.ca
418-656-8711 ext. 3841
Mélanie Nadeau, MSc
Contact
melanie.nadeau@criucpq.ulaval.ca
418-656-8711 ext. 3490
Laurent Biertho, MD
principal investigator · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion